StockIQ.techUnited Therapeutics Corporation (UTHR) Stock Analysis
Free AI-powered analysis and research for United Therapeutics Corporation stock
Sector: Healthcare
UTHR snapshot
Data as of 3 Nov 2026 close. Updated daily.
United Therapeutics Corporation scores 100/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 94% of its 52-week range, up 36.5% over the past year. Latest reported figures show a profit margin of 41.6%, return on equity of 19.3% and revenue growth of -1.9%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Excellent Profit Margin (41.6%): +10
- Strong Liquidity (5.73 Current Ratio): +8
- Strong ROE (19.3%): +5
- Strong Long-term Uptrend: +8
- Strong Momentum (+36.5% over 1 year): +8
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full UTHR report
United Therapeutics Corporation (UTHR) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze UTHR Now →📰 Latest Update
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
Wed, October 28, 2026 at 1:00 PM UTC 3 min read
Analysts predict that United Therapeutics (UTHR) will report a decline in earnings in the upcoming quarter, primarily due to increased competition and potential pricing pressures in the biotech sector. This anticipated downturn could impact investor sentiment, as it may signal challenges in maintaining revenue growth. Investors should closely monitor the company's pipeline developments and market dynamics to gauge future performance and potential recovery.